Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts

Research Group

Gastrointestinal and Other Cancers

Status

Active, not recruiting

NCT ID

NCT03085004

The purpose of this study is to evaluate the efficacy and safety of chemotherapeutic pancreatic cyst ablation using ethanol lavage followed by the infusion of a dual-agent chemotherapeutic cocktail (paclitaxel + gemcitabine) compared with alcohol-free saline lavage followed by infusion of the same dual-agent chemotherapeutic cocktail (paclitaxel + gemcitabine) for the ablation of pancreatic cystic neoplasms using endoscopic ultrasound guided fine needle infusion (EUS-FNI) for agent delivery.

Intervention

Ethanol, Normal saline, Paclitaxel + Gemcitabine admixture

Condition

Pancreatic Cyst, EUS-FNA

Investigators

Matthew T. Moyer, MD, MS

See list of participating sites